Breadcrumbs

Medical (MSL-HCP) Meeting Summaries

Overview

Medical meeting summaries are designed for scientific enablement conversations between Medical Science Liaisons (MSLs) and Healthcare Professionals. These summaries capture clinical questions, evidence shared, and scientific follow-ups, helping you deliver value and maintain continuity across interactions.

Use this summary type for:

  • MSL to HCP scientific discussions

  • Clinical data presentations

  • Evidence gap identification

  • Guideline and protocol discussions

What's Included

Every medical summary contains five key sections focused on scientific exchange and evidence-based dialogue.

1. Scientific Summary

What it is: A concise narrative (max 200 words) that captures the scientific discussion in one paragraph.

What it covers:

  • HCP's clinical or scientific questions

  • Data, studies, or evidence discussed

  • Safety and efficacy points covered

  • Guideline alignment or protocol considerations

  • Evidence gaps or unresolved questions identified

  • Scientific direction or outcomes

Example:

The discussion focused on the use of [Product X] in [Condition A], specifically regarding whether the drug should be discontinued if a patient becomes unwell or experiences an acute exacerbation. The MSL clarified that the decision to stop [Product X] is ultimately a clinical one, as the term "unwell" is broad and patient-specific. The Summary of Product Characteristics (SPC) for [Product X] does not provide explicit guidance for discontinuation in the context of hospital admission due to general illness but does specify stopping the drug in cases of hypersensitivity reactions or unresolved parasitic infections. In the two phase 3 clinical trials for [Product X] in [Condition A], the drug was not routinely discontinued during exacerbations; discontinuation was reserved for adverse events, infections unresponsive to treatment, or certain laboratory abnormalities. The HCP confirmed that their main question was about management during acute flare-ups, and the MSL provided evidence that continuation is standard unless specific discontinuation criteria are met. The HCP indicated that local guidelines and policies are being updated to potentially include [Product X] for [Condition A], pending formulary approval.

Why it matters: Provides a complete scientific context for the interaction, making it easy to maintain continuity and prepare for follow-ups.

2. HCP Scientific Needs

What it is: Up to 3 bullet points specifying the clinical questions, data requirements, or evidence gaps the HCP needs addressed.

What it covers:

  • Specific clinical questions requiring answers

  • Data or literature requests

  • Practice context or patient population considerations

  • Guideline interpretation needs

  • Protocol development requirements

Example:

  • Clarification on whether [Product X] should be stopped during acute [Condition A] exacerbations.

  • Information on SPC and clinical trial discontinuation criteria for [Product X] in [Condition A].

  • Support for updating local [Condition A] guidelines to include [Product X].

Why it matters: Clearly identifies what the HCP needs from you scientifically, making your follow-up preparation targeted and efficient.

3. MSL Actions

What it is: Up to 3 numbered, specific actions you need to take, with literature source types and clear deliverables.

Format: Each action follows this structure: [Action description]. Success: [What success looks like], Due: [Timeline]

What makes it special: Actions now reference the type of literature source (e.g., peer-reviewed article, data-on-file, clinical trial data) so you know exactly what to provide.

Example:

  1. Provide a summary of SPC guidance and clinical trial discontinuation criteria for [Product X] in [Condition A] to the HCP and respiratory pharmacist. Success: HCP and pharmacist receive and acknowledge the summary, Due: Within 2 weeks.

  2. Offer educational support on [Product X] use in [Condition A] for the local team as needed. Success: Educational needs assessed and session scheduled if required, Due: Within 1 month.

  3. Liaise with the respiratory pharmacist to ensure all queries are addressed and facilitate further contact if needed. Success: Pharmacist receives contact details and support offer, Due: Within 1 week.

Why it matters: Eliminates ambiguity about what evidence to provide and when, making your scientific support more precise and professional.

4. HCP Commitments

What it is: A numbered list of scientific follow-ups the HCP agreed to undertake.

What it includes:

  • Reviewing data packs or literature

  • Scheduling deep-dive sessions

  • Discussing study interest or participation

  • Internal stakeholder consultations

  • Protocol updates or reviews

When it appears:

  • Shows numbered commitments when the HCP made specific promises

  • Displays "No HCP commitments" when none were secured

Example:

No HCP commitments.

(or when commitments exist)

  1. Prepare and collect data on a local cohort of [Condition A] patients with frequent exacerbations and high/intermittent biomarkers in anticipation of potential [Product X] use.

  2. Consider departmental educational sessions on biomarker management and trial data if [regulatory body] guidance becomes favourable.

Why it matters: Tracks HCP engagement and helps you understand their level of interest and commitment to scientific collaboration.

5. Unresolved Scientific Items

What it is: Bullet points highlighting clinical questions, evidence gaps, or items requiring additional clarification.

What it flags:

  • Questions that couldn't be fully answered

  • Evidence not yet available

  • Ongoing regulatory or guideline uncertainties

  • Areas requiring further research or discussion

Example:

  • Lack of long-term (beyond 52 weeks) efficacy and safety data for [Product X] in [Condition A].

  • Uncertainty regarding the most clinically relevant biomarker threshold for patient selection.

  • Need for real-world mortality and severe exacerbation data specific to [Product X] in [Condition A].

Or when nothing is unresolved:

No unresolved items.

Why it matters: Maintains scientific integrity by clearly documenting what remains uncertain, helping you prioritize future evidence generation and communication.

Key Features

✅ Scientific Precision: Focuses on clinical questions, data, and evidence—no commercial content
✅ Literature Source Identification: Actions specify what type of evidence to provide
✅ Evidence Gap Tracking: Clearly documents what's known and what's still uncertain
✅ Guideline Alignment: Captures protocol and guideline discussions for context
✅ Automatic PII Protection: All identifying information removed while preserving clinical context

How to Use These Summaries

Immediately after an interaction:

  • Review MSL Actions to prepare literature and materials

  • Note HCP Scientific Needs for evidence gathering

  • Check Unresolved Scientific Items for medical information requests

For territory scientific planning:

  • Use HCP Scientific Needs to identify common evidence gaps across your territory

  • Track Unresolved Scientific Items to inform medical affairs strategy

  • Analyze HCP Commitments to measure scientific engagement

For medical strategy:

  • Aggregate Unresolved Scientific Items to identify priority evidence generation needs

  • Use Scientific Summaries for internal stakeholder updates

  • Track patterns in HCP Scientific Needs for educational program development

For compliance:

  • Summaries maintain clear separation between scientific exchange and promotional activity

  • All content traceable to actual conversation

  • PII protection ensures regulatory compliance